Aims: To determine how excessive daytime sleepiness (EDS) and impaired cognition (CI) contribute to health-related quality of life (HRQL) in heart failure (HF).
Introduction
Poor health-related quality of life (HRQL) is more common in adults with heart failure (HF) than that of age and gender-matched controls. 1 Individuals with HF have been noted to have worse HRQL than those with cancer or other serious illnesses. 2 In advanced HF, HRQL that fails to improve within one month after hospital discharge predicts a shortened time to subsequent hospitalization or death. 3 A variety of factors has been identified as being associated with the poor HRQL of HF, including symptom burden and cognitive impairment. 4 Although poor sleep quality has been shown to be significantly correlated with impairments in HRQL in other patient populations, 5 it has only recently been recognized as a contributor to poor HRQL in HF. Redeker and Hilkert found that self-reported sleep quality and lack of sleep continuity were associated with impaired HRQL in stable systolic HF patients. 6 In another study, HF patients who had difficulties maintaining sleep, initiating sleep, and early morning awakenings had reduced HRQL. 7 Numerous individual contributors to poor HRQL have been identified but these contributors rarely occur in isolation. A recent study explored the contribution of impaired cognition to poor HRQL in adults with HF. 8 They found that HF severity, age, depressive symptoms, and total recall memory explained 55% of the variance in HRQL, but the individual contribution of memory to the amount of variance in HRQL explained was minimal (1%). However, in prior work we found that impaired cognition was commonly associated with poor sleep in adults with HF. 9 Therefore, the purpose of this study was to determine how excessive daytime sleepiness (EDS) and impaired cognition together contribute to poor HRQL in HF.
Background HF patients commonly report difficulties initiating and maintaining sleep. 7 A majority report poor sleep quality, 10 and many have poor sleep continuity. 11 Half of HF patients report insomnia-related symptoms, including EDS. 12 In one sample, the most frequently reported problems were inability to sleep flat (51%), restless sleep (44%), trouble falling asleep (40%), and awakening early (39%). 13 Numerous factors impair sleep and cause EDS including stress, 14 15 Regardless of the cause, poor sleep dulls cognitive processing, impairing information processing, memory, vigilance, judgment, motivation, and decision-making. 16 The impact varies depending on the severity of the sleep interruption. 17 But even modest sleep restriction (6 hours/night) causes clear impairment in cognition after 7 days; mild sleep fragmentation (e.g. nocturia) takes longer to impair cognition. 18 
Methods
This was a preplanned analysis from a prospective cohort comparison study. The methods used in this study have been described in detail previously and are summarized here. 19 Subjects were enrolled from three sites in the northeastern U.S. Institutional review board approval was obtained at each site and all subjects gave informed consent. Data were obtained at enrollment, 3-and 6-months during faceto-face visits. In all, 280 subjects were enrolled and 242 completed the 6-month follow-up. Reasons for attrition included death (n=6), too ill to continue (n=7), refusal to continue or withdrawal (n=5), and loss to follow-up (n=20).
A prospective cohort design allowed us to have well-characterized cohorts for testing hypotheses about the effects of EDS and impaired cognition on HRQL. At baseline we identified a cohort with EDS and a control group without EDS. These groups were further divided into those with and without cognitive impairment, as described below. The result was four groups or cohorts for comparison ( Figure 1 ). We hypothesized that cohort membership at enrollment would be a significant predictor of HRQL 6-months later.
Sample
We enrolled adults with chronic HF confirmation based on echocardiographic and clinical evidence. All participants had to be currently or previously symptomatic (stage C HF). Potential subjects had to be able to participate in the study (i.e., adequate vision, hearing, and English literacy). The
Telephone Interview for Cognitive Status (TICS) was used assure that we did not enroll anyone with frank dementia; anyone with a TICS score below 24 was excluded. 20 Otherwise eligible individuals were excluded if they lived in a long term care setting or worked nights or rotating shifts, or if they had renal failure requiring dialysis, an imminently terminal illness, plans to move out of the area, or a history of serious drug or alcohol abuse within the past year. Individuals with major depression were excluded and because EDS is a prominent symptom of depression so it would be difficult to separate out the two problems. Major depressive illness was screened first by a review of the medical record; patients identified as having major depressive illness were not invited to participate. In addition, everyone was screened with the 9-item Patient Health Questionnaire (PHQ-9). 21 Anyone reporting 5 or more of the 9 symptoms more than half the days in the past 2 weeks was excluded if one of the symptoms was depressed mood or anhedonia. Most of the data were collected during home visits and by abstraction from the medical record.
Measurement
EDS was measured using the Epworth Sleepiness Scale. 22 Respondents rate the likelihood of falling asleep in eight boring situations such as sitting in a car as a passenger using a 4-point Likert scale ranging from never dozing (0) to high chance of dozing (3). Test-retest reliability (r = 0.82) and internal consistency (α = 0.88) have been established in addition to its single factor structure. Scores are summed, with higher scores indicating higher sleepiness, or categorized as sleepy or not sleepy. At a cutpoint of 11, the Epworth Sleepiness Scale has a sensitivity of 93.5% and a specificity of 100% for distinguishing pathological from normal sleepiness. However, adults with HF do not report EDS as commonly as others, 23 perhaps because of the sympathetic stimulation associated with HF. So, to make sure that we capture some variability in EDS, we used a cut-point score ≥6 to indicate EDS on the advice of the instrument author.
A battery of five neuropsychological tests measuring attention, memory, and executive function was administered at enrollment and used to allocate participants to cohorts. 24 The battery included a overall quality of life, social interference, and self-efficacy. 26 Internal consistency of the instrument ranges from .78 -.95 for all domains except self-efficacy (alpha=.62). Higher scores indicate better HRQL.
The Functional Outcomes of Sleep Questionnaire (FOSQ) is a 30-item self-report measure designed to assess the impact of EDS on HRQL. 27 The FOSQ has established content validity, test-retest reliability (r = 0.91), and internal consistency (α = 0.96). Higher scores indicate better HRQL.
Sociodemographic characteristics were self-reported at enrollment. Most clinical information (e.g., comorbid illnesses, HF type and duration) was gathered from the medical record. Comorbidity was scored using the Charlson Index; higher scores indicate more comorbid illnesses. 28 To decrease subject burden, depression was measured over time using the short form of the Patient Health Questionnaire (PHQ-2). Information on symptoms in response to activities was gathered by trained research assistants using a structured interview. 29 A cardiologist used the interview data to assign a New York Heart Association (NYHA) score for every subject. Length of time with HF was based on information collected from a historical search of each subject's medical record.
Data on sleep disordered breathing was obtained from the medical record at the time of enrollment. If no documentation of recent polysomnography was found in the medical record, sleep was assessed in the home using Embletta (Medcare, Buffalo, NY), a sensitive and specific screening device useful in quantifying the apnea hypopnea index (AHI) in persons with suspected sleep disordered breathing. 30 Embletta data were scored by expert technicians. An AHI ≥ 5 was used to classify subjects as having sleep disordered breathing. 31 In addition, during each home visit, medicines were noted and later categorized to identify those known to cause daytime somnolence (e.g., sedative hypnotics).
Analysis
Graphical techniques were used to assess the distributional assumptions of the KCCQ overall summary score, the FOSQ total score, and the subscales of both measures. Transformations to normality were applied as necessary. Specifically, the KCCQ overall summary score and the FOSQ total score were squared in order to meet distribution assumptions for modeling. Linear mixed effects models were used to model the square-transformed total scores on both scales and transformed subscales that were approximately normally distributed. Back transformed estimates were also calculated in order to interpret the effects on the original scale scores. Non-normal subscales were modeled via generalized estimating equations with an ordered, cumulative logit link. The primary analysis examined the cohort differences in the outcome scores. Other potential covariates such as NHYA class, income, depressive symptoms, perceived health, and medication adherence were included in the model via a backward stepwise technique. All models were adjusted for age, race, income, gender, data collection occasion, and data collection site. Analyses were performed using SAS 9.2.
Results
Descriptive details of the sample are shown in Table 1 . Overall, the sample was predominately male, white, well-educated, and financially comfortable. Most participants were overweight and functionally compromised. Significant demographic differences were evident among the cohorts defined by presence or absence of cognitive impairment and EDS. The two cohorts with cognitive impairment were older, less likely to be white, more likely to have less than a high school education, and less likely to be employed than either cohort without cognitive impairment. The cohort with the highest perceived overall health had EDS but no cognitive impairment. The number of comorbid illnesses was highest in those with cognitive impairment. Depression was highest in the cohort with both EDS and impaired cognition. No differences in the prevalence of sleep disordered breathing or the number of medications known to cause daytime somnolence were identified. Table 2 describes how the HRQL total scores and subscales changed over the course of the six month study. Overall, HRQL scores improved from baseline to study completion among patients who completed the study.
The final model for KCCQ overall summary scores across all visits is shown in Table 3 . The two cohorts with EDS had significantly lower KCCQ overall scores compared to the cohort without either EDS or cognitive impairment; on average, the cognitively impaired EDS cohort had a 33 point lower KCCQ score (p<0.001) and the non-impaired EDS cohort had a 25 point lower KCCQ score (p=0.030). In addition, poor functional class moderated the relationship between cohort membership and HRQL.
Subjects in NYHA classes III and IV had, on average, 36 and 49 point lower KCCQ total scores than a comparable subject in class I or II (both p<0.001), based on a total possible score of 100. There were no significant interactions with cohorts or over time. In results not shown in the table, the cohort with both EDS and impaired cognition had significantly worse KCCQ subscale scores compared to the cohort without EDS or impaired cognition (p<0.05), while the cohort with only EDS had significantly worse physical limitation scores (p=0.036).
The FOSQ total score final model across all visits is shown in Table 4 . Based on a total possible score of 20, the two cohorts with EDS had 8 and 7 point lower FOSQ total scores, respectively, compared to a similar subject in the cohort without EDS or impaired cognition (both p<0.001). Again, NYHA moderated the relationship between cohort membership and HRQL; subjects in NYHA classes III and IV had, on average, 3 and 5 point lower scores than a comparable subject in class I or II (p=0.017 and p<0.001, respectively). There were no significant interactions with cohorts or over time. For the FOSQ subscale scores, both cohorts with EDS had significantly higher general productivity (with cognitive impairment: p<0.001, without cognitive impairment: p=0.016), activity level (both p<0.001), and vigilance (both p<0.001) subscale scores (results not shown) compared to the cohort without either EDS or cognitive impairment.
Discussion
Excessive daytime sleepiness contributes to HRQL, but when it is combined with cognitive impairment, it is even more powerful as a predictor of poor HRQL in adults with HF. The double jeopardy of EDS and impaired cognition was especially prominent in subjects who were physically functionally impaired. These results suggest that NYHA class III and class IV patients with HF should be suspected of EDS and cognitive impairment. And, those with cognitive impairment and/or EDS may well have poor HRQL. We found no differences in sleep disordered breathing among the cohorts, illustrating that we cannot assume that HF patients with EDS are those with sleep apnea. Further research is needed to determine if interventions can improve EDS and if EDS improves, does HRQL improve as well.
These results build on those from Pressler et al who found that impaired memory contributed only 1% of the variance in HRQL of HF patients. 8 In our study, we found that impaired cognition, which includes memory, contributed significantly to HRQL but only when combined with EDS. This suggests that it is the symptom burden that affects HRQL more than changes in cognition, as suggested by Heo et al. 4 Pressler et al also found that HF severity was an important contributor to HRQL, consistent with our results showing NYHA functional class as a moderator of the relationship between cohort group and HRQL. Again, NYHA reflects symptom burden, which continues to be identified as an important determinant of poor HRQL. 32, 33 The finding that EDS contributes significantly to poor HRQL is consistent with prior results demonstrating that poor sleep quality impairs HRQL in adults with HF. 6, 7 However, neither of those investigative teams tested EDS as the symptom indicator of poor HRQL. Identifying a symptom of focus is important because screening for EDS is easy. As we showed in a prior study in which four different approaches to measuring EDS were compared, the measure of EDS that was most sensitive to daytime dysfunction was a single Likert item measured on a 10-point (1-10) scale. Patients with a score ≥4 were 2.4 times more likely to have daytime dysfunction than those with a score <4. 34 Adding this single question to a screening form at clinic visits could help to identify patients needing intervention. survival in adults with HF and central sleep apnea. 35 After 3 months, the group randomized to CPAP had fewer episodes of apnea and hypopnea, lower norepinephrine levels, and greater increases in the mean nocturnal oxygen saturation, ejection fraction, and distance walked in 6 minutes, but long-term outcomes were not improved at 2 years. There were no differences between the control and CPAP groups in atrial natriuretic peptide levels, HRQL, or the number of hospitalizations. The CANPAP study was stopped early for low enrollment.
Few other sleep promoting approaches have been tested in HF patients and no other approach has been tested in anything other than a pilot study or a small clinical trial. Preliminary research suggests that exercise may improve total sleep time and HRQL, 36 not all studies support this result. 37 More study is needed to understand the effects on sleep and the amount and type of exercise needed to have an effect. Fortunately, such a trial is underway testing the effect of a supervised exercise training program in recently hospitalized HF patients attending a disease management program. 38 Daytime sleepiness may be easier to influence than cognitive impairment. Pressler reviewed studies of cognitive impairment in adults with HF and concluded that 25-50% of HF patients have impaired cognition. 39 This impairment appears to differ from typical vascular dementia in that some studies have shown that cognition may improve over time in HF patients treated with ACE inhibitor therapy or aerobic exercise. 40 , 41 Pressler et al have had some preliminary success in improving memory in HF patients with cognitive impairment. 42 HF patients were randomly assigned to a computerized plasticity-based cognitive training intervention called Brain Fitness. Compared to an active control intervention group receiving health education, the Brain Fitness participants improved significantly over time in delayed recall memory and both groups improved over time in list learning, delayed recall memory, psychomotor speed, and performance of independent activities of daily living.
The observation that HRQL improved over time in all of the groups was surprising. Others have noted an increase in HRQL over time even without an intervention, which they attributed to passing through a high-risk period following hospitalization in one study. 43 We provided no intervention, nor were our participants necessarily recently hospitalized, so the improvement may have been due to social desirability effects, better engagement in care, reactivity to the measures, or behavioral activation due to engagement in the study.
Limitations of this current study include limited generalizability, as many patients were ineligible for inclusion in the study if the cohort they qualified for was already full. This sample was also younger, better educated, and more financially comfortable than many HF patients in the general community.
Strengths of the study include the relatively large proportion of minority participants and the thoroughness with which HRQL and cognitive impairment were measured.
In summary, in this study we demonstrated that EDS is associated with poor HRQL and the combination of EDS and impaired cognition represents double jeopardy for HF patients. EDS is easily screened and could be used to identify patients at risk for poor HRQL. Testing of interventions designed to improve EDS in HF patients are needed. Square-transformed Kansas City Cardiomyopathy Questionnaire total score was modeled. 
NYHA=New York Heart Association

